# A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2

> **NCT03580278** · PHASE1 · COMPLETED · sponsor: **Affibody** · enrollment: 33 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** ABY-035/AFO2

## Key facts

- **NCT ID:** NCT03580278
- **Lead sponsor:** Affibody
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-13
- **Primary completion:** 2020-09-22
- **Final completion:** 2020-09-22
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03580278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03580278, "A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03580278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*